Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer

Li-Jen Cheng & Mohamed Ismail Abdul Aziz · 2021-03-08